AbCellera Biologics (ABCL) Q4 2024 earnings summary

Executive summary

• Transitioned from a platform/partnership model to a clinical-stage biotech, focusing on advancing the internal pipeline and reducing new discovery partnerships.

• Advanced two lead programs, ABCL635 and ABCL575, toward Clinical Trial Application filings in Q2 2025, with robust preclinical pipeline and diversified exposure across therapeutic areas.

• Completed move to new headquarters and established clinical manufacturing capabilities, with facility launch planned for 2025.

• Ended 2024 with over $800 million in available liquidity, positioning for strategic execution and clinical trial initiations.

• Initiated nine new partner programs and advanced three additional molecules into the clinic, totaling 96 programs and 16 clinic molecules.

Financial highlights

• Revenue for 2024 was $28.8 million, down from $38 million in 2023, mainly from research fees and milestones.

• Net loss for 2024 was $163 million ($0.55 per share), compared to $146.4 million ($0.51 per share) in 2023.

• R&D expenses were $167.3 million, slightly down from $175.7 million in 2023.

• Cash and equivalents at year-end were $652.9 million, with $186–$190 million in committed government funding, totaling about $840 million in liquidity.

• Operating expenses for 2024 totaled $343.6 million, up from $275.2 million in 2023.

Outlook and guidance

• Expect to initiate Phase 1 clinical trials for ABCL635 and ABCL575 in 2025, with first readouts in 2026.

• Plan to nominate two additional development candidates per year and complete platform investments by mid-2025.

• Intend to submit 1–3 INDs per year over the next five years.

• Anticipate similar cash usage for operating activities in 2025, with PP&E investments halved and weighted to first half.

• Confident in liquidity to fund operations well beyond the next three years.